All articles by Umesh Ellichipuram

Umesh Ellichipuram

Boston Pharma signs out-licensing agreement with GSK

Boston Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a three-year out-license and option agreement to advance multiple pre-phase two programmes.

Anima and Takeda to develop mRNA modulators for neurological diseases

Anima Biotech and Takeda Pharmaceutical are collaborating to discover and develop mRNA translation modulators for neurological diseases.

Hoth Therapeutics and UCRI to perform critical studies for HT-006 antibiotic

Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.

Merck adds assembly production unit in France for Covid-19 vaccines

Merck is adding a €25m, single-use assembly production unit at its Life Science Center (LSC) in Molsheim, France, to manufacture Covid-19 vaccines and other therapies.

Gland Pharma signs Sputnik V Covid-19 vaccine manufacturing deal with RDIF

Indian pharmaceutical company Gland Pharma has signed an agreement with the Russian Direct Investment Fund (RDIF) for the manufacture of nearly 252 million doses of the Sputnik V Covid-19 vaccine.

AstraZeneca to supply 500,000 doses of Covid-19 antibody to the US

AstraZeneca (AZ) has signed an agreement with the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) for the supply of up to 500,000 additional doses of its Covid-19 antibody treatment for $205m.

Aurinia reports favourable assessment of LUPKYNIS in ICER

Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.

Novartis unveils positive data from studies of Zolgensma to treat SMA

Novartis has unveiled positive data from two studies of new gene therapy Zolgensma, which demonstrated that children with spinal muscular atrophy (SMA) treated pre-symptomatically achieved age-appropriate motor milestones, including sitting, standing and walking.

Grace to expand pharma portfolio with Albemarle’s business acquisition

US-based company W R Grace is set to expand its pharma portfolio with the acquisition of Albemarle’ Fine Chemistry Services business (FCS) for about $570m.

Merck signs agreement to buy Pandion Therapeutics for $1.85bn

Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates.